Cti Biopharma Corp SC 13D and SC 13D/A reports

Location
3101 Western Avenue, Suite 800, Seattle, WA
State of incorporation
Delaware
Fiscal year end
December 31
Data updated at
7/19/2024, 10:41 AM
Form type Sec Links Description Filing date Reporting date
SC 13D/A Report AMENDMENT NO. 9 TO THE SCHEDULE 13D Jun 28, 2023
SC 13D/A Report AMENDMENT NO. 8 TO THE SCHEDULE 13D Aug 11, 2022
SC 13D/A Report GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. SCHEDULE 13D/A(#4E Jul 22, 2022
SC 13D/A Report GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. SCHEDULE 13D/A(#3) Jun 17, 2022
SC 13D/A Report AMENDMENT NO. 7 TO THE SCHEDULE 13D Mar 15, 2021
SC 13D/A Report GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. Mar 12, 2020
SC 13D/A Report AMENDMENT NO. 6 TO THE SCHEDULE 13D Mar 4, 2020
SC 13D/A Report GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. -- SCHEDULE 13D/A Feb 13, 2020
SC 13D/A Report AMENDMENT NO. 5 TO THE SCHEDULE 13D Feb 4, 2020
SC 13D Report GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. -- SCHEDULE 13D Feb 20, 2018
SC 13D/A Report AMENDMENT NO. 4 TO THE SCHEDULE 13D Feb 12, 2018
SC 13D/A Report AMENDMENT NO. 3 TO THE SCHEDULE 13D Jun 14, 2017
SC 13D/A Report AMENDMENT NO. 2 TO THE SCHEDULE 13D Jan 14, 2016
SC 13D/A Report AMENDMENT NO. 1 TO THE SCHEDULE 13D Jan 11, 2016
SC 13D Report SCHEDULE 13D Dec 11, 2015